<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Yestino - The Signal · COPD</title><link>https://yestino.com/entities/copd-0bb770</link><description>Every event involving COPD</description><language>en</language><atom:link href="https://yestino.com/entities/copd-0bb770/feed.xml" rel="self" type="application/rss+xml"/><item><title>AstraZeneca&apos;s experimental COPD drug aced late-stage trials, boosting blockbuster sales hopes</title><link>https://yestino.com/events/astrazeneca-s-experimental-copd-drug-aced-late-stage-trials-f4d324</link><guid isPermaLink="true">https://yestino.com/events/astrazeneca-s-experimental-copd-drug-aced-late-stage-trials-f4d324</guid><pubDate>Tue, 08 Sep 2026 12:30:44 GMT</pubDate><description>The drug reduced flare-ups in a broader patient population than existing COPD biologics, with U.S.
Sources: Quartz</description></item></channel></rss>